5 completed, 2 withdrawn, 1 recruiting, 1 unknown. 4 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Withdrawn 1 |
Follow CDI: new trials by email Literature Review of CDI trials Research Report on CDI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Gut Microbiota and Its Associated Resistome in FMT Donors and Recipients Due to Recurrent Clostridiodes Difficile Infection CDI | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 24 | 2024-09-15 | 2024-08-01 | |
| VE303 for Prevention of Recurrent Clostridioides Difficile Infection VE303, Placebo - Clostridium Difficile, Clostridium Difficile Infections | Phase 3 | Recruiting | Vedanta Biosciences, Inc. | 852 | 2024-05-20 | 2026-09-29 |
| Precision Antimicrobial STewardship for Clostridioides DIfficile Prevention CDI-risk Classification Tool - CDI | Completed | Intermountain Health Care, Inc. | 13319 | 2021-05-01 | 2022-08-19 | |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection No Intervention - Clostridium Difficile, Clostridium Difficile Infection | Withdrawn | ProgenaBiome | 2020-03-02 | 2025-06-05 | ||
| Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI Vancomycin 125 MG po BID - CDI | Phase 4 | Withdrawn | Creighton University | 2019-10-29 | 2020-01-27 | |
| The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule - Clostridium Difficile Infection, C.Difficile Diarrhea | Phase 2 | Completed | University of Wisconsin, Madison | 1 | 2019-03-21 | 2021-03-15 |
| Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection VE303, Placebo - Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection | Phase 2 | Completed | Vedanta Biosciences, Inc. | 79 | 2019-02-08 | 2023-07-03 |
| Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Vancomycin, Placebo - Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection | Phase 2 | Completed | University of Wisconsin, Madison | 79 | 2018-05-21 | 2025-05-25 |
| Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection CP101 - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection | Phase 2 | Completed | Finch Research and Development LLC. | 132 | 2018-05-01 | 2022-08-30 |
Clostridium Infections (6) · Diabetes Insipidus, Neurogenic (1) · Dysentery (1) · Enterocolitis, Pseudomembranous (1)
Bacterial Infections (6) · Bacterial Infections and Mycoses (6) · Gram-Positive Bacterial Infections (6) · Infections (6) · Digestive System Diseases (2) · Gastroenteritis (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Diabetes Insipidus (1) · Endocrine System Diseases (1) · Enterocolitis (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1)
Vancomycin (2) · Fecal Microbiota Transplantation (1)
University of Wisconsin, Madison (2) · Vedanta Biosciences, Inc. (2) · Creighton University (1) · Finch Research and Development LLC. (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Intermountain Health Care, Inc. (1) · ProgenaBiome (1)
United States (8) · Canada (3) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1) · Hungary (1) · Ireland (1) · Israel (1) · Italy (1)
Darrell Pardi, MD (1) · Nasia Safdar, MD PhD (1) · Nasia Safdar, MD, PhD (1) · Sabine Hazan, MD (1) · Zain Kassam, MD, MPH (1)